Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,018 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.
Joensuu H, Vehtari A, Riihimäki J, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Cirilli C, Braconi C, Bordoni A, Magnusson MK, Linke Z, Sufliarsky J, Federico M, Jonasson JG, Dei Tos AP, Rutkowski P. Joensuu H, et al. Among authors: nilsson b. Lancet Oncol. 2012 Mar;13(3):265-74. doi: 10.1016/S1470-2045(11)70299-6. Epub 2011 Dec 6. Lancet Oncol. 2012. PMID: 22153892 Review.
One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Monge OR, Bono P, Kallio R, Vehtari A, Leinonen M, Alvegård T, Reichardt P. Joensuu H, et al. Among authors: nilsson b. JAMA. 2012 Mar 28;307(12):1265-72. doi: 10.1001/jama.2012.347. JAMA. 2012. PMID: 22453568 Clinical Trial.
Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib.
Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P. Joensuu H, et al. Among authors: nilsson b. Cancer. 2014 Aug 1;120(15):2325-33. doi: 10.1002/cncr.28669. Epub 2014 Apr 15. Cancer. 2014. PMID: 24737415 Free PMC article. Clinical Trial.
KIT and PDGFRA mutations and the risk of GI stromal tumor recurrence.
Joensuu H, Rutkowski P, Nishida T, Steigen SE, Brabec P, Plank L, Nilsson B, Braconi C, Bordoni A, Magnusson MK, Sufliarsky J, Federico M, Jonasson JG, Hostein I, Bringuier PP, Emile JF. Joensuu H, et al. Among authors: nilsson b. J Clin Oncol. 2015 Feb 20;33(6):634-42. doi: 10.1200/JCO.2014.57.4970. Epub 2015 Jan 20. J Clin Oncol. 2015. PMID: 25605837
Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Ramadori G, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Nilsson B, Sihto H, Bono P, Kallio R, Junnila J, Alvegård T, Reichardt P. Joensuu H, et al. Among authors: nilsson b. J Clin Oncol. 2016 Jan 20;34(3):244-50. doi: 10.1200/JCO.2015.62.9170. Epub 2015 Nov 2. J Clin Oncol. 2016. PMID: 26527782 Clinical Trial.
Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib: An Exploratory Analysis of a Randomized Clinical Trial.
Joensuu H, Wardelmann E, Sihto H, Eriksson M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S, Hohenberger P, Al-Batran SE, Schlemmer M, Bauer S, Nilsson B, Kallio R, Junnila J, Vehtari A, Reichardt P. Joensuu H, et al. Among authors: nilsson b. JAMA Oncol. 2017 May 1;3(5):602-609. doi: 10.1001/jamaoncol.2016.5751. JAMA Oncol. 2017. PMID: 28334365 Free PMC article. Clinical Trial.
Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H, Eriksson M, Sundby Hall K, Reichardt A, Hermes B, Schütte J, Cameron S, Hohenberger P, Jost PJ, Al-Batran SE, Lindner LH, Bauer S, Wardelmann E, Nilsson B, Kallio R, Jaakkola P, Junnila J, Alvegård T, Reichardt P. Joensuu H, et al. Among authors: nilsson b. JAMA Oncol. 2020 Aug 1;6(8):1241-1246. doi: 10.1001/jamaoncol.2020.2091. JAMA Oncol. 2020. PMID: 32469385 Free PMC article. Clinical Trial.
2,018 results